Want to see HK:2607 full AI Analyst Report?
Top Page
Shanghai Pharmaceuticals Holding Co
(2607)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$12.00
▲(4.90% Upside)
Action:Reiterated
Date:08/28/26
The score is driven primarily by solid financial performance (strong TTM revenue growth and improved TTM cash flow), tempered by thin margins and a recent leverage uptick. Technical indicators are a significant drag given weak momentum and price trading below key moving averages. Valuation helps offset these risks with a low P/E and an attractive dividend yield.
Positive Factors
Revenue Re-acceleration
The sharp top-line re-acceleration indicates stronger demand, distribution volumes, or product contribution. If sustained, broader healthcare coverage and channel reach can support growth across both manufacturing and distribution.
Negative Factors
Structurally Thin Margins
Low profitability leaves limited protection against procurement, logistics, labor, or pricing pressure. The decline in EBIT margin despite strong revenue growth suggests cost or product-mix challenges that could constrain durable earnings expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Re-acceleration
The sharp top-line re-acceleration indicates stronger demand, distribution volumes, or product contribution. If sustained, broader healthcare coverage and channel reach can support growth across both manufacturing and distribution.
Read all positive factors
Shanghai Pharmaceuticals Holding Co (2607) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$63.44B
Dividend Yield4.87%
Average Volume (3M)1.45M
Price to Earnings (P/E)12.6
Beta (1Y)0.70
Revenue Growth8.02%
EPS Growth-17.74%
CountryHK
Employees49,608
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)1.27
Shares Outstanding919,072,700
10 Day Avg. Volume1,906,009
30 Day Avg. Volume1,450,479
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.50
Price to Sales (P/S)0.13
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.49
Revenue Forecast (FY)HK$296.56B
Shanghai Pharmaceuticals Holding Co Business Overview & Revenue Model
Company Description
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, dev...
How the Company Makes Money
The company primarily makes money through two major revenue streams: (1) pharmaceutical and healthcare product distribution, and (2) pharmaceutical manufacturing and sales.
1) Pharmaceutical and healthcare product distribution (wholesale/logistic...
Shanghai Pharmaceuticals Holding Co Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
56
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 288.45B | 283.58B | 275.25B | 260.30B | 231.98B | 215.82B |
| Gross Profit | 31.17B | 30.42B | 30.63B | 30.93B | 30.49B | 28.54B |
| EBITDA | 8.68B | 14.37B | 12.06B | 10.90B | 12.44B | 10.55B |
| Net Income | 4.75B | 5.72B | 4.55B | 3.77B | 5.62B | 5.09B |
Balance Sheet | ||||||
| Total Assets | 241.31B | 233.15B | 221.21B | 211.97B | 198.13B | 163.44B |
| Cash, Cash Equivalents and Short-Term Investments | 45.98B | 43.08B | 44.38B | 40.67B | 37.01B | 22.39B |
| Total Debt | 65.92B | 49.48B | 47.79B | 42.90B | 38.56B | 31.69B |
| Total Liabilities | 148.02B | 143.36B | 137.47B | 131.65B | 120.13B | 104.37B |
| Stockholders Equity | 78.33B | 75.89B | 71.68B | 68.52B | 67.06B | 49.36B |
Cash Flow | ||||||
| Free Cash Flow | 7.64B | 3.83B | 3.43B | 2.26B | 2.06B | 942.55M |
| Operating Cash Flow | 9.91B | 6.15B | 5.83B | 5.23B | 4.74B | 5.06B |
| Investing Cash Flow | -2.14B | -3.98B | 415.98M | -2.49B | -12.47B | -6.02B |
| Financing Cash Flow | -10.84B | -5.65B | -1.86B | 231.85M | 12.14B | 1.57B |
Shanghai Pharmaceuticals Holding Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.03B | 13.10 | 7.00% | 4.45% | 6.47% | 8.10% | |
65 Neutral | HK$48.37B | 5.83 | 8.33% | 5.14% | 2.78% | 7.71% | |
61 Neutral | HK$63.44B | 12.63 | 6.21% | 4.87% | 8.02% | -17.74% | |
57 Neutral | HK$593.46M | 10.91 | 7.70% | 6.25% | 14.28% | 0.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$430.01M | -6.31 | -273.18% | ― | 5.52% | 56.54% | |
40 Underperform | HK$826.96M | -9.16 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:2607
Shanghai Pharmaceuticals Holding Co
11.03
-0.62
-5.33%
HK:0673
China Health Group
0.31
-0.19
-38.00%
HK:1099
Sinopharm Group Co
15.36
-2.86
-15.71%
HK:1931
IVD Medical Holding Limited
0.50
-9.94
-95.21%
HK:2192
Medlive Technology Co., Ltd.
7.06
-6.07
-46.24%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.50
-0.18
-3.15%
Shanghai Pharmaceuticals Holding Co Corporate Events
Shanghai Pharmaceuticals Posts Strong H1 2026 Profit and Declares Cash Dividend
Aug 27, 2026
Shanghai Pharmaceuticals Holding Co. has released its unaudited interim results for the six months ended 30 June 2026, prepared under Chinese Accounting Standards and reviewed by its board and audit committee. The company’s leadership has co...
Shanghai Pharmaceuticals Announces Interim Cash Dividend for First Half of 2026
Aug 27, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an interim ordinary cash dividend for the six months ended 30 June 2026, declaring a payout of RMB 1 per 10 shares for the financial year ending 31 December 2026. Key operational dates for H...
Shanghai Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 17, 2026
Shanghai Pharmaceuticals Holding Co. has scheduled a board meeting for 27 August 2026 to review and approve the interim results for the six months ended 30 June 2026, covering the performance of the company and its subsidiaries. The board will als...
Shanghai Pharmaceuticals Finalizes Participation in Shanghai Biomedical Phase II Fund
Jul 24, 2026
Shanghai Pharmaceuticals Holding Co. has signed a partnership agreement to participate in the establishment of the Shanghai Biomedical Phase II Fund, formalizing plans first announced on 18 July 2026. The move underscores the company’s commi...
Shanghai Pharmaceuticals Joins RMB Biomedical Fund in Connected Transaction
Jul 17, 2026
Shanghai Pharmaceuticals Holding Co. plans to join a new Shanghai Biomedical Phase II Fund as a limited partner, committing RMB300 million alongside several state-backed and industry investors, including Shanghai Pharmaceutical (Group) and Junshi ...
Shanghai Pharmaceuticals Revises Vote Data on 2025 Profit Distribution Plan
Jul 8, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has issued a clarification to its earlier disclosure on the voting results for its 2025 profit distribution plan at the annual general meeting. The company corrected the reported vote breakdown for A shar...
Shanghai Pharmaceuticals AGM Secures Strong Shareholder Backing and Governance Stability
Jun 25, 2026
Shanghai Pharmaceuticals reported that its 2025 annual general meeting was duly convened in Shanghai in compliance with PRC company law and its articles of association. The meeting was chaired by board chairman Yang Qiuhua, with most directors and...
Shanghai Pharmaceuticals Sets Final 2025 Dividend and Details HK Tax Treatment
Jun 25, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has declared a final ordinary cash dividend of RMB 3.5 per 10 shares for the financial year ended 31 December 2025, with shareholder approval obtained on 25 June 2026. For Hong Kong shareholders, the divi...
Shanghai Pharmaceuticals Details Board Line-Up and Governance Committees
Jun 25, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has announced the current composition of its board of directors, naming Yang Qiuhua as chairman alongside three other executive directors, one non-executive director, an employee representative director a...
Shanghai Pharmaceuticals Names Zhao Yong Employee Representative Director to Ninth Board
Jun 17, 2026
Shanghai Pharmaceuticals Holding Co. has appointed Zhao Yong as the employee representative director on the company’s ninth board, following his election at the employee representative meeting on June 16, 2026. His term will align with the n...
Shanghai Pharmaceuticals Updates 2025 Final Dividend and Tax Arrangements
Jun 3, 2026
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an updated final cash dividend for the year ended 31 December 2025, confirming a payout of RMB 3.5 per 10 shares subject to shareholder approval on 25 June 2026. Key timetable details for Ho...
Shanghai Pharmaceuticals Sets June 2026 AGM to Approve Results, Funding Plans and Board Changes
Jun 3, 2026
Shanghai Pharmaceuticals Holding Co. has called its annual general meeting for 25 June 2026 in Shanghai, where shareholders will review the company’s 2025 annual report, board report, final accounts, and the financial budget for 2026. The AG...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.